Highlights from

TOXINS 2019

International Neurotoxin Association (INA) annual meeting

Copenhagen 16-19 January 2019

ASPIRE: High patient and clinician satisfaction

Dr Gerard Francisco (TIRR Memorial Hermann Hospital, USA) focused on real-world onabotulinum toxin A treatment utilisation. He evaluated efficacy across multiple aetiologies of spasticity from the Adult Spasticity International Registry (ASPIRE) study. Dr Francisco examined data  derived from the international, multicentre, prospective, observational registry  from adult patients with spasticity either due to stroke (56%), multiple sclerosis, cerebral palsy, traumatic brain injury, spinal cord injury, or other illnesses, treated with onabotulinum toxin A. In total, 730 participants, of whom 37% were previously treatment-naïve to botulinum toxins, received at least one onabotulinum toxin A treatment. Total dosages per treatment session ranged from 45 to 1,038 units. The most common symptoms prompting treatments were equinovarus foot and clenched fist (in stroke). Most physicians and patients reported being "satisfied" or "extremely satisfied" with treatment that helped manage spasticity. The majority of physicians and patients stated they would "definitely" or "probably" continue therapy. No new safety signals were identified.

These 1-year interim data from the ASPIRE study, presented by Dr Francisco, continue to support safety and effectiveness of onabotulinum toxin A treatment for spasticity in clinical practice. Despite variation in dosing, patient and physician satisfaction across aetiologies was high.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.